

Special Issue

Non-Hodgkin Lymphomas

Message from the Guest Editor

Recently, new insights into the genetic/molecular basis of non-Hodgkin lymphomas have paved the way to the development of targeted therapies, and a better understanding of the interplay between the patient's immune system and cancer cells has led to the development of several innovative immunotherapies. Of these strategies, two that have recently generated much excitement are chimeric antigen receptor T-cell therapy and immune checkpoint inhibitors. The efficacy of these approaches is limited to a relatively small number of patients and, for this reason, there is an urgent need to identify positive or negative (bio)markers that predict treatment response or severe adverse events.

Guest Editor

Prof. Dr. Pier Luigi Zinzani

1. IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
2. Istituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università degli Studi, Bologna, Italy

Deadline for manuscript submissions

closed (10 July 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/67343

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)